Skip to main content
Top
Published in: Immunity & Ageing 1/2017

Open Access 01-12-2017 | Research

Herpes virus seroepidemiology in the adult Swedish population

Authors: Jan Olsson, Eloise Kok, Rolf Adolfsson, Hugo Lövheim, Fredrik Elgh

Published in: Immunity & Ageing | Issue 1/2017

Login to get access

Abstract

Background

Herpes viruses establish a life-long latency and can cause symptoms during both first-time infection and later reactivation. The aim of the present study was to describe the seroepidemiology of Herpes simplex type 1 (HSV1), Herpes simplex type 2 (HSV2), Cytomegalovirus (CMV), Varicella Zoster virus (VZV) and Human herpes virus type 6 (HHV6) in an adult Swedish population (35–95 years of age).

Methods

Presence of antibodies against the respective viruses in serum from individuals in the Betula study was determined with an enzyme-linked immunosorbent assay (ELISA). Singular samples from 535 persons (53.9% women, mean age at inclusion 62.7 ± 14.4 years) collected 2003-2005 were analyzed for the five HHVs mentioned above. In addition, samples including follow-up samples collected 1988–2010 from 3,444 persons were analyzed for HSV.

Results

Prevalence of HSV1 was 79.4%, HSV2 12.9%, CMV 83.2%, VZV 97.9%, and HHV6 97.5%. Herpes virus infections were more common among women (p = 0.010) and a lower age-adjusted HSV seroprevalence was found in later birth cohorts (p < 0.001). The yearly incidence of HSV infection was estimated at 14.0/1000.

Conclusion

Women are more often seropositive for HHV, especially HSV2. Age-adjusted seroprevalence for HSV was lower in later birth cohorts indicating a decreasing childhood and adolescent risk of infection.
Literature
1.
go back to reference Arvin A, et al. Human Herpesviruses Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. p. 1. online resource (1408 p.).CrossRef Arvin A, et al. Human Herpesviruses Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. p. 1. online resource (1408 p.).CrossRef
2.
go back to reference Ball MJ. Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved? Can J Neurol Sci. 1982;9(3):303–6.CrossRefPubMed Ball MJ. Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved? Can J Neurol Sci. 1982;9(3):303–6.CrossRefPubMed
3.
go back to reference Steel AJ, Eslick GD. Herpes viruses increase the risk of Alzheimer’s disease: a meta-analysis. J Alzheimers Dis. 2015;47(2):351–64.CrossRefPubMed Steel AJ, Eslick GD. Herpes viruses increase the risk of Alzheimer’s disease: a meta-analysis. J Alzheimers Dis. 2015;47(2):351–64.CrossRefPubMed
4.
5.
go back to reference Lovheim H, et al. Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement. 2015;11(6):593–9.CrossRefPubMed Lovheim H, et al. Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement. 2015;11(6):593–9.CrossRefPubMed
6.
go back to reference Lovheim H, et al. Herpes simplex infection and the risk of Alzheimer’s disease: A nested case-control study. Alzheimers Dement. 2015;11(6):587–92.CrossRefPubMed Lovheim H, et al. Herpes simplex infection and the risk of Alzheimer’s disease: A nested case-control study. Alzheimers Dement. 2015;11(6):587–92.CrossRefPubMed
7.
go back to reference Ji YN, et al. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep. 2012;39(6):6537–46.CrossRefPubMed Ji YN, et al. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep. 2012;39(6):6537–46.CrossRefPubMed
9.
go back to reference Wu YP, et al. Herpes simplex virus type 1 and type 2 infection increases atherosclerosis risk: evidence based on a meta-analysis. Biomed Res Int. 2016;2016:2630865.PubMedPubMedCentral Wu YP, et al. Herpes simplex virus type 1 and type 2 infection increases atherosclerosis risk: evidence based on a meta-analysis. Biomed Res Int. 2016;2016:2630865.PubMedPubMedCentral
10.
go back to reference Tarter KD, et al. Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. J Infect Dis. 2014;209(6):837–44.CrossRefPubMed Tarter KD, et al. Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. J Infect Dis. 2014;209(6):837–44.CrossRefPubMed
11.
go back to reference Watson AM, et al. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med. 2013;43(5):1023–31.CrossRefPubMed Watson AM, et al. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med. 2013;43(5):1023–31.CrossRefPubMed
12.
go back to reference Chen MH, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014;76(4):285–91.CrossRefPubMed Chen MH, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014;76(4):285–91.CrossRefPubMed
13.
go back to reference Liao CH, et al. High prevalence of herpes zoster in patients with depression. J Clin Psychiatry. 2015;76(9):e1099–104.CrossRefPubMed Liao CH, et al. High prevalence of herpes zoster in patients with depression. J Clin Psychiatry. 2015;76(9):e1099–104.CrossRefPubMed
15.
go back to reference Kobayashi N, et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer’s disease. Biochem Biophys Res Commun. 2013;430(3):907–11.CrossRefPubMed Kobayashi N, et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer’s disease. Biochem Biophys Res Commun. 2013;430(3):907–11.CrossRefPubMed
16.
go back to reference Agostini S, et al. Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2015;49(1):229–35.CrossRef Agostini S, et al. Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2015;49(1):229–35.CrossRef
17.
go back to reference Shim SM, et al., Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly. J Alzheimers Dis. 2017;55(1):293-301. Shim SM, et al., Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly. J Alzheimers Dis. 2017;55(1):293-301.
18.
go back to reference Olsson J, et al., HSV presence in brains of individuals without dementia: the TASTY brain series. Dis Model Mech. 2016;9(11):1349-55. Olsson J, et al., HSV presence in brains of individuals without dementia: the TASTY brain series. Dis Model Mech. 2016;9(11):1349-55.
19.
go back to reference Cohen JA, et al. Herpes simplex virus seroprevalence and seroconversion among active duty US air force members with HIV infection. J Clin Virol. 2016;74:4–7.CrossRefPubMed Cohen JA, et al. Herpes simplex virus seroprevalence and seroconversion among active duty US air force members with HIV infection. J Clin Virol. 2016;74:4–7.CrossRefPubMed
21.
go back to reference Saadatian-Elahi M, et al. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur J Epidemiol. 2007;22(6):405–9.CrossRefPubMed Saadatian-Elahi M, et al. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur J Epidemiol. 2007;22(6):405–9.CrossRefPubMed
23.
go back to reference Nilsson LG, et al. The Betula prospective cohort study: Memory, health and aging. Aging Neuropsychol Cognit. 1997;4(1):1–32.CrossRef Nilsson LG, et al. The Betula prospective cohort study: Memory, health and aging. Aging Neuropsychol Cognit. 1997;4(1):1–32.CrossRef
24.
go back to reference Schaie KW. A general model for the study of developmental problems. Psychol Bull. 1965;64:92–107.CrossRefPubMed Schaie KW. A general model for the study of developmental problems. Psychol Bull. 1965;64:92–107.CrossRefPubMed
25.
go back to reference Schaie KW. Quasi-experimental research designs in the psychology of aging. In: Birren JE, editor. Handbook of the psychology of aging. New York: Van Nostrand; 1977. p. 39–58. Schaie KW. Quasi-experimental research designs in the psychology of aging. In: Birren JE, editor. Handbook of the psychology of aging. New York: Van Nostrand; 1977. p. 39–58.
26.
go back to reference Juto P, Settergren B. Specific serum IgA, IgG and IgM antibody determination by a modified indirect ELISA-technique in primary and recurrent herpes simplex virus infection. J Virol Methods. 1988;20(1):45–55.CrossRefPubMed Juto P, Settergren B. Specific serum IgA, IgG and IgM antibody determination by a modified indirect ELISA-technique in primary and recurrent herpes simplex virus infection. J Virol Methods. 1988;20(1):45–55.CrossRefPubMed
27.
go back to reference Sundstrom P, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62(12):2277–82.CrossRefPubMed Sundstrom P, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62(12):2277–82.CrossRefPubMed
29.
go back to reference Kilgore PE, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70 Suppl 1:S111–8.CrossRefPubMed Kilgore PE, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70 Suppl 1:S111–8.CrossRefPubMed
30.
go back to reference Nielsen L, Vestergaard BF. Competitive ELISA for detection of HHV-6 antibody: seroprevalence in a danish population. J Virol Methods. 1996;56(2):221–30.CrossRefPubMed Nielsen L, Vestergaard BF. Competitive ELISA for detection of HHV-6 antibody: seroprevalence in a danish population. J Virol Methods. 1996;56(2):221–30.CrossRefPubMed
31.
go back to reference Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol. 2000;16(3):149–57.CrossRefPubMed Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol. 2000;16(3):149–57.CrossRefPubMed
32.
go back to reference Saxinger C, et al. Antibody reactivity with HBLV (HHV-6) in U.S. populations. J Virol Methods. 1988;21(1-4):199–208.CrossRefPubMed Saxinger C, et al. Antibody reactivity with HBLV (HHV-6) in U.S. populations. J Virol Methods. 1988;21(1-4):199–208.CrossRefPubMed
33.
go back to reference Ihira M, et al. Serological examination of human herpesvirus 6 and 7 in patients with coronary artery disease. J Med Virol. 2002;67(4):534–7.CrossRefPubMed Ihira M, et al. Serological examination of human herpesvirus 6 and 7 in patients with coronary artery disease. J Med Virol. 2002;67(4):534–7.CrossRefPubMed
34.
go back to reference Parker CA, Weber JM. An enzyme-linked immunosorbent assay for the detection of IgG and IgM antibodies to human herpesvirus type 6. J Virol Methods. 1993;41(3):265–75.CrossRefPubMed Parker CA, Weber JM. An enzyme-linked immunosorbent assay for the detection of IgG and IgM antibodies to human herpesvirus type 6. J Virol Methods. 1993;41(3):265–75.CrossRefPubMed
35.
36.
go back to reference Ahlfors K. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis. 1984;16(4):335–7.CrossRefPubMed Ahlfors K. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis. 1984;16(4):335–7.CrossRefPubMed
38.
go back to reference Nilsson BO, et al. Antinuclear antibodies in the oldest-old women and men. J Autoimmun. 2006;27(4):281–8.CrossRefPubMed Nilsson BO, et al. Antinuclear antibodies in the oldest-old women and men. J Autoimmun. 2006;27(4):281–8.CrossRefPubMed
39.
go back to reference Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50(11):1439–47.CrossRefPubMed Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50(11):1439–47.CrossRefPubMed
40.
go back to reference Simanek AM, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6(2):e16103.CrossRefPubMedPubMedCentral Simanek AM, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6(2):e16103.CrossRefPubMedPubMedCentral
41.
go back to reference Schmaltz HN, et al. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc. 2005;53(5):747–54.CrossRefPubMed Schmaltz HN, et al. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc. 2005;53(5):747–54.CrossRefPubMed
42.
go back to reference Hecker M, et al. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004;86(1):41–4.CrossRefPubMed Hecker M, et al. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004;86(1):41–4.CrossRefPubMed
43.
go back to reference Bunzli D, et al. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25–74 in 1992–93: a population-based study. BMC Infect Dis. 2004;4:10.CrossRefPubMedPubMedCentral Bunzli D, et al. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25–74 in 1992–93: a population-based study. BMC Infect Dis. 2004;4:10.CrossRefPubMedPubMedCentral
44.
go back to reference Jonsson MK, et al. Minimal change in HSV-2 seroreactivity: a cross-sectional Swedish population study. Scand J Infect Dis. 2006;38(5):357–65.CrossRefPubMed Jonsson MK, et al. Minimal change in HSV-2 seroreactivity: a cross-sectional Swedish population study. Scand J Infect Dis. 2006;38(5):357–65.CrossRefPubMed
45.
go back to reference Xu F, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–73.CrossRefPubMed Xu F, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–73.CrossRefPubMed
46.
go back to reference Bradley H, et al. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999–2010. J Infect Dis. 2014;209(3):325–33.CrossRefPubMed Bradley H, et al. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999–2010. J Infect Dis. 2014;209(3):325–33.CrossRefPubMed
47.
go back to reference Woestenberg PJ, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis. 2016;16:364.CrossRefPubMedPubMedCentral Woestenberg PJ, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis. 2016;16:364.CrossRefPubMedPubMedCentral
48.
go back to reference Itzhaki RF, et al., Microbes and Alzheimer’s Disease. J Alzheimers Dis. 2016;51(4):979-84. Itzhaki RF, et al., Microbes and Alzheimer’s Disease. J Alzheimers Dis. 2016;51(4):979-84.
49.
go back to reference Langa KM, et al., A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51-58. Langa KM, et al., A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51-58.
50.
go back to reference Qiu C, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm. Sweden Neurology. 2013;80(20):1888–94.CrossRefPubMed Qiu C, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm. Sweden Neurology. 2013;80(20):1888–94.CrossRefPubMed
Metadata
Title
Herpes virus seroepidemiology in the adult Swedish population
Authors
Jan Olsson
Eloise Kok
Rolf Adolfsson
Hugo Lövheim
Fredrik Elgh
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2017
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/s12979-017-0093-4

Other articles of this Issue 1/2017

Immunity & Ageing 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.